Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

VNDA

Insider Sentiment (TTM):

Last Purchase:2025-08-07Last Sale:2026-03-02Shares Purchased (TTM):0Shares Sold (TTM):344,342

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:42,346,751Shares Outstanding:59,459,982Institutional Ownership Pct.:71.22%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	56	54	85	70	81	112	102	100	103	125	136	183
Debt Securities Available For Sale Excluding Accru…	114	148	179	224	245	229	272	276	285	269	252	307
Accounts Receivable Net Current	60	57	55	51	45	45	47	43	42	37	34	29
Inventory Net	2	2	2	2	2	2	2	2	1	2	1	1
Prepaid Expense And Other Assets Current	33	32	27	21	22	20	15	12	8	7	9	16
Assets Current	264	293	347	367	395	408	439	432	439	439	433	537
Property Plant And Equipment Net	3	2	2	2	2	2	2	2	2	2	2	2
Operating Lease Right Of Use Asset	15	5	4	4	5	5	6	6	6	7	7	7
Finance Lease Right Of Use Asset	-	7	7	5	5	5	5	-	-	-	0	-
Finite Lived Intangible Assets Net	113	115	117	109	111	112	114	116	118	119	121	17
Deferred Income Tax Assets Net	-	-	0	103	97	89	81	79	77	75	75	68
Assets	412	434	489	601	625	632	656	645	651	653	648	642
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	70	61	68	48	57	45	39	39	40	38	38	33
Liabilities Current	164	136	145	118	121	104	100	89	94	93	88	85
Operating Lease Liability Noncurrent	15	3	3	3	4	4	5	5	6	7	7	7
Finance Lease Liability Noncurrent	-	4	4	3	3	3	3	-	-	-	0	-
Other Liabilities Noncurrent	10	10	10	11	10	9	10	9	9	9	9	6
Liabilities	192	153	162	135	138	121	118	104	109	109	104	99
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	726	724	721	719	717	715	713	710	707	704	700	697
Accumulated Other Comprehensive Income Loss Net Of…	0	0	1	1	0	0	0	1	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-506	-443	-395	-254	-231	-204	-174	-169	-164	-160	-155	-153
Stockholders Equity	220	281	327	466	486	511	539	541	543	544	545	543
Liabilities And Stockholders Equity	412	434	489	601	625	632	656	645	651	653	648	642
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	60	60	59	59	59	59	58	58	58	58	58	58
Shares Outstanding	60	60	59	59	59	59	58	58	58	58	58	58

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.94%	-5.95%	-18.94%	-	-	-	-	-	-	-	-	-
2025	2.84%	13.27%	12.32%	11.50%	5.40%	23.71%	11.11%	56.25%	72.92%	28.92%	14.38%	14.38%
2024	2.00%	12.77%	23.35%	-3.19%	-18.26%	-12.94%	2.59%	-4.18%	-12.35%	9.73%	-6.33%	3.39%
2023	-	-	-	-	-	-	15.38%	24.85%	10.95%	13.27%	0.98%	13.51%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.61	2.16	2.39	3.12	3.25	3.93	4.39	4.85	4.68	4.71	4.94	6.32
Quick Ratio	1.40	1.91	2.19	2.92	3.05	3.71	4.22	4.70	4.58	4.62	4.82	6.12
Working Capital	100.46M	157.59M	202.10M	249.63M	273.43M	303.99M	338.91M	343.30M	345.39M	346.08M	345.25M	451.74M
Leverage & Debt
Debt to Equity	0.87	0.54	0.49	0.29	0.28	0.24	0.22	0.19	0.20	0.20	0.19	0.18
Debt Ratio	0.47	0.35	0.33	0.22	0.22	0.19	0.18	0.16	0.17	0.17	0.16	0.15
Efficiency & Turnover
Asset Turnover TTM	0.42	0.41	0.38	0.34	0.32	0.31	0.30	0.30	0.28	0.27	0.30	0.34
Days Sales Outstanding TTM	88.56	85.04	85.87	80.28	77.91	73.70	74.60	68.87	75.68	62.91	64.11	50.50
Receivables Turnover TTM	4.12	4.29	4.25	4.55	4.69	4.95	4.89	5.30	4.82	5.80	5.69	7.23
Per Share Metrics
Diluted EPS TTM	-4.56	-4.03	-3.74	-1.42	-1.13	-0.76	-0.33	-0.28	-0.19	-0.08	0.04	0.20
Free Cash Flow Per Share TTM	-2.37	-2.14	-1.87	-1.40	-1.12	-0.98	-0.28	-0.31	-0.10	-0.20	0.22	0.44
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	93.74%	94.18%	93.96%	94.44%	94.40%	94.34%	94.31%	93.62%	93.03%	92.42%	92.32%	91.70%
Operating Profit Margin TTM	-86.07%	-73.64%	-69.95%	-57.10%	-49.55%	-35.98%	-20.46%	-19.64%	-17.84%	-14.18%	-7.24%	-0.11%
Net Profit Margin TTM	-127.41%	-109.99%	-102.02%	-39.70%	-32.90%	-21.98%	-9.51%	-8.59%	-6.00%	-2.75%	1.30%	5.56%
Growth Metrics
Net Revenue Growth (1Y)	6.02%	8.16%	8.72%	11.12%	11.78%	13.37%	3.18%	-9.91%	-23.63%	-30.81%	-24.27%	-17.86%
Net Income Growth (1Y)	310.61%	441.37%	1,066.53%	413.78%	512.58%	805.05%	-853.29%	-239.24%	-173.32%	-130.64%	-60.02%	81.30%
EPS Growth (1Y)	302.21%	432.89%	1,051.07%	406.57%	504.56%	793.19%	-843.34%	-237.46%	-172.35%	-130.24%	-60.66%	78.32%
Valuation Metrics
P/E TTM	-1.34	-1.72	-2.36	-3.50	-4.16	-6.07	-14.74	-16.67	-30.10	-48.56	96.51	21.11
P/B TTM	1.67	1.46	1.59	0.63	0.57	0.53	0.52	0.50	0.61	0.44	0.44	0.46
P/S TTM	1.71	1.89	2.41	1.39	1.37	1.33	1.40	1.43	1.81	1.34	1.26	1.17
Market Cap	368.59M	410.87M	519.76M	294.87M	278.45M	268.64M	278.53M	273.25M	328.95M	237.40M	242.15M	248.48M
Enterprise Value	312.24M	360.15M	438.52M	227.18M	200.08M	159.32M	178.90M	172.28M	225.53M	111.77M	105.86M	64.83M
Calculated Values
Free Cash Flow TTM	-143.01M	-127.30M	-110.44M	-82.95M	-65.91M	-57.39M	-16.25M	-18.20M	-5.53M	-11.77M	12.42M	25.56M
Net Debt	-56.35M	-50.72M	-81.24M	-67.68M	-78.37M	-109.32M	-99.64M	-100.97M	-103.42M	-125.63M	-136.29M	-183.66M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-02Sale

Owner: Moran, Kevin Patrick

Title: SVP, CFO & Treasurer

Shares: 42,442

Price/Share: $8.27

Value: $350,995.34

Shares Owned: 411,380

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Polymeropoulos, Mihael Hr…

Title: President and CEO

Shares: 156,235

Price/Share: $8.17

Value: $1,276,439.95

Shares Owned: 2,704,496

Relationship: Director,Officer,Other

Ownership: Direct

2026-03-02Sale

Owner: Wijkstrom, Joakim

Title: SVP, Chief Marketing Officer

Shares: 30,800

Price/Share: $8.27

Value: $254,716.00

Shares Owned: 333,469

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Birznieks, Gunther

Title: SVP, Business Development

Shares: 42,431

Price/Share: $8.27

Value: $350,904.37

Shares Owned: 494,197

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Williams, Timothy

Title: SVP & General Counsel

Shares: 42,434

Price/Share: $8.27

Value: $350,929.18

Shares Owned: 377,450

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-02	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	42,442	8.27	$350,995.34	411,380	4
2026-03-02	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Sale	156,235	8.17	$1,276,439.95	2,704,496	4
2026-03-02	Wijkstrom, Joakim	Officer	SVP, Chief Marketing Officer	Direct	Sale	30,800	8.27	$254,716.00	333,469	4
2026-03-02	Birznieks, Gunther	Officer	SVP, Business Development	Direct	Sale	42,431	8.27	$350,904.37	494,197	4
2026-03-02	Williams, Timothy	Officer	SVP & General Counsel	Direct	Sale	42,434	8.27	$350,929.18	377,450	4
2026-02-23	Honore, Tage	Director	-	Direct	Sale	30,000	8.03	$240,900.00	93,469	4
2025-08-07	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.15	$41,500.00	2,335,731	4
2025-06-13	Mitchell, Stephen Ray	Director	-	Direct	Sale	7,000	4.59	$32,130.00	97,082	4
2025-05-21	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.39	$43,900.00	2,325,731	4
2025-05-16	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	20,000	4.22	$84,400.00	2,315,731	4
2025-03-06	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	5.01	$50,100.00	2,295,731	4
2025-03-05	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	5.02	$50,200.00	2,285,731	4
2025-03-03	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.71	$47,100.00	2,275,731	4
2025-02-28	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.76	$47,600.00	2,361,730	4
2025-02-27	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.76	$47,600.00	2,351,730	4
2025-02-26	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.77	$47,700.00	2,341,730	4
2025-02-25	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Purchase	10,000	4.46	$44,600.00	2,331,730	4
2025-02-21	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Purchase	2,000	4.39	$8,780.00	355,763	4
2024-11-14	Mitchell, Stephen Ray	Director	-	Direct	Sale	5,000	5.17	$25,850.00	44,857	4
2024-07-29	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	2,251	5.92	$13,325.92	228,763	4
2024-03-05	Wijkstrom, Joakim	Officer	SVP, Chief Marketing Officer	Direct	Sale	9,229	4.21	$38,854.09	129,789	4
2024-03-05	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	8,902	4.20	$37,388.40	231,014	4
2024-03-05	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Sale	24,288	4.13	$100,309.44	1,871,730	4
2024-03-05	Williams, Timothy	Officer	SVP & General Counsel	Direct	Sale	8,941	4.18	$37,373.38	196,825	4
2024-03-05	Birznieks, Gunther	Officer	SVP, Business Development	Direct	Sale	8,684	4.13	$35,864.92	313,569	4
2023-08-21	Wijkstrom, Joakim	Officer	SVP, Chief Marketing Officer	Direct	Sale	3,724	5.84	$21,748.16	113,816	4
2023-08-10	Mitchell, Stephen Ray	Director	-	Direct	Sale	6,500	6.05	$39,325.00	29,328	4
2023-07-28	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	2,212	6.30	$13,935.60	120,714	4
2023-06-15	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	16,000	6.29	$100,640.00	122,926	4
2023-06-13	Williams, Timothy	Officer	SVP & General Counsel	Direct	Sale	14,600	6.56	$95,776.00	88,913	4
2023-03-03	Birznieks, Gunther	Officer	SVP, Business Development	Direct	Sale	8,268	6.26	$51,757.68	205,980	4
2023-03-03	Polymeropoulos, Mihael Hr…	Director,Officer,Other	President and CEO	Direct	Sale	22,538	6.25	$140,862.50	1,476,902	4
2023-03-03	Williams, Timothy	Officer	SVP & General Counsel	Direct	Sale	8,301	6.25	$51,881.25	103,513	4
2023-03-03	Moran, Kevin Patrick	Officer	SVP, CFO & Treasurer	Direct	Sale	5,968	6.28	$37,479.04	138,926	4
2023-03-03	Wijkstrom, Joakim	Officer	SVP, Chief Marketing Officer	Direct	Sale	4,113	6.32	$25,994.16	117,540	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

71.22%

Inst. Shares: 42,346,751

Shares Outstanding: 59,459,982

2025-12-31

64.06%

Inst. Shares: 37,753,286

Shares Outstanding: 58,930,157

2025-09-30

69.23%

Inst. Shares: 40,906,622

Shares Outstanding: 59,091,478

2025-06-30

70.10%

Inst. Shares: 41,357,337

Shares Outstanding: 58,993,990

2025-03-31

69.18%

Inst. Shares: 40,489,380

Shares Outstanding: 58,527,775

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	42,346,751	59,459,982	71.22%
2025-12-31	37,753,286	58,930,157	64.06%
2025-09-30	40,906,622	59,091,478	69.23%
2025-06-30	41,357,337	58,993,990	70.10%
2025-03-31	40,489,380	58,527,775	69.18%
2024-12-31	40,349,583	58,149,087	69.39%
2024-09-30	41,034,390	58,261,961	70.43%
2024-06-30	40,676,577	58,220,838	69.87%
2024-03-31	40,404,528	57,760,940	69.95%
2023-12-31	43,711,591	57,380,975	76.18%
2023-09-30	45,385,068	57,519,031	78.90%
2023-06-30	50,359,869	57,453,916	87.65%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vanda Pharmaceuticals Inc. (VNDA) — SEC Financial Statements & Analysis

Vanda Pharmaceuticals Inc. (VNDA) is a pharmaceutical preparations company, incorporated in DE. Vanda Pharmaceuticals Inc. trades on Nasdaq as: VNDA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vanda Pharmaceuticals Inc. reported a 6.02% year-over-year revenue growth, a Gross Profit Margin of 93.74% (TTM), a Debt-to-Equity ratio of 0.87x, a Price-to-Sales (P/S) ratio of 1.71x (TTM), a Price-to-Book (P/B) ratio of 1.67x (TTM), at a market cap of $368.59M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 6.02%
Gross Profit Margin TTM: 93.74%
Debt To Equity: 0.87x
P/S TTM: 1.71x
P/B TTM: 1.67x
Market Cap: $368.59M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vanda Pharmaceuticals Inc. in?

Vanda Pharmaceuticals Inc. (VNDA) operates in the Pharmaceutical Preparations industry.

What is VNDA's market cap?

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalization of $368.59M as of 2026-06-30.

What exchange does VNDA trade on?

Vanda Pharmaceuticals Inc. (VNDA) trades on the Nasdaq.

Where is Vanda Pharmaceuticals Inc. incorporated?

Vanda Pharmaceuticals Inc. is incorporated in DE.